Journal Home
Search for

Volume 103, Issue 7, Pages 975-994 (July 2009)


View previous. 4 of 17 View next.

The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use

Stephanie C. MansonaCorresponding Author Informationemail address, Ruth E. Browna, Annamaria Cerullib, Carlos Fernandez Vidaurrec

Received 18 June 2008; accepted 5 January 2009. published online 16 April 2009.

Summary 

Oral corticosteroids (OCS) are a key part of therapy regimens for a diverse variety of conditions. Despite their efficacy, they are associated with a wide variety of adverse events. The purpose of this review was to identify the range of adverse events that have been reported to be related to oral corticosteroids, examine the factors that influence their incidence and estimate the economic burden caused by these adverse events. In 61 identified studies, 21 different categories of OCS related adverse events were reported with increased fracture risk being the category most frequently described. Most studies that examined factors linked to the incidence of OCS related adverse events found that dose, age, gender, duration of use, treatment history, smoking habits or cholesterol level were influential in determining risk. Additionally, a cumulative economic analysis of selected adverse events found the annual cost of treating these events in the UK to be at least £165 per patient taking OCS. The clinical and economic burden of OCS related adverse events highlights the need for OCS sparing therapies to be developed.

a United BioSource Corporation, 20 Bloomsbury Square, London WCIA 2NS, UK

b Novartis Pharma AG, Basel, Switzerland

c Novartis Pharma AG, East Hanover, NJ, USA

Corresponding Author InformationCorresponding author. Tel.: +44 207 299 4596.

PII: S0954-6111(09)00003-1

doi:10.1016/j.rmed.2009.01.003


View previous. 4 of 17 View next.